[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0203531A3 - Quetiapine granules and process for their preparation and their use - Google Patents

Quetiapine granules and process for their preparation and their use

Info

Publication number
HUP0203531A3
HUP0203531A3 HU0203531A HUP0203531A HUP0203531A3 HU P0203531 A3 HUP0203531 A3 HU P0203531A3 HU 0203531 A HU0203531 A HU 0203531A HU P0203531 A HUP0203531 A HU P0203531A HU P0203531 A3 HUP0203531 A3 HU P0203531A3
Authority
HU
Hungary
Prior art keywords
preparation
quetiapine granules
quetiapine
granules
Prior art date
Application number
HU0203531A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203531(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0203531A2 publication Critical patent/HUP0203531A2/hu
Publication of HUP0203531A3 publication Critical patent/HUP0203531A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
HU0203531A 1999-09-21 2000-09-18 Quetiapine granules and process for their preparation and their use HUP0203531A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation
PCT/GB2000/003598 WO2001021179A1 (en) 1999-09-21 2000-09-18 Quetiapine granules

Publications (2)

Publication Number Publication Date
HUP0203531A2 HUP0203531A2 (hu) 2003-02-28
HUP0203531A3 true HUP0203531A3 (en) 2004-12-28

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203531A HUP0203531A3 (en) 1999-09-21 2000-09-18 Quetiapine granules and process for their preparation and their use

Country Status (37)

Country Link
US (3) US6599897B1 (hu)
EP (1) EP1218009B1 (hu)
JP (1) JP2003509461A (hu)
KR (1) KR100748823B1 (hu)
CN (3) CN1188130C (hu)
AR (1) AR032596A1 (hu)
AT (1) ATE288272T1 (hu)
AU (1) AU776292B2 (hu)
BG (1) BG65469B1 (hu)
BR (1) BR0014107A (hu)
CA (1) CA2383131A1 (hu)
CO (1) CO5180585A1 (hu)
CZ (1) CZ301585B6 (hu)
DE (1) DE60017923T2 (hu)
DK (1) DK1218009T3 (hu)
EE (1) EE200200150A (hu)
EG (1) EG24226A (hu)
ES (1) ES2235941T3 (hu)
GB (2) GB9922271D0 (hu)
HK (1) HK1047706B (hu)
HU (1) HUP0203531A3 (hu)
IL (2) IL148440A0 (hu)
IS (1) IS2139B (hu)
MX (1) MXPA02002627A (hu)
MY (1) MY130208A (hu)
NO (1) NO320908B1 (hu)
NZ (1) NZ517549A (hu)
PL (1) PL198824B1 (hu)
PT (1) PT1218009E (hu)
RU (1) RU2256453C2 (hu)
SI (1) SI1218009T1 (hu)
SK (1) SK286884B6 (hu)
TR (1) TR200200716T2 (hu)
TW (1) TWI226832B (hu)
UA (1) UA73529C2 (hu)
WO (1) WO2001021179A1 (hu)
ZA (1) ZA200201709B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
EP1879874A2 (en) * 2005-04-21 2008-01-23 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
US20100178333A1 (en) 2006-01-25 2010-07-15 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
EP2021325A2 (en) * 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
BRPI0714586A2 (pt) * 2006-07-28 2013-05-07 Farmaprojects S A formulaÇço farmacÊutica de liberaÇço prolongada de metropolol e processo para a sua preparaÇço
WO2008034041A2 (en) * 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
CN101610774B (zh) * 2006-11-03 2012-04-04 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
EP2112923A1 (en) * 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
ES2352299T3 (es) 2007-02-14 2011-02-17 Laboratorios Lesvi, S.L. Composiciones farmacéuticas que contienen fumarato de quetiapina.
AU2009219286B2 (en) * 2008-02-27 2012-02-09 Intercontinental Great Brands Llc Multi-region confectionery
ES2402342T3 (es) 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Composición de quetiapina
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
CA2927380C (en) * 2009-12-31 2017-07-04 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8703802B2 (en) 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
ES2054259T3 (es) * 1989-08-31 1994-08-01 Takeda Chemical Industries Ltd Composicion de vitamina b12.
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
US20040228914A1 (en) 2004-11-18
UA73529C2 (uk) 2005-08-15
SK286884B6 (sk) 2009-07-06
ZA200201709B (en) 2003-05-28
EG24226A (en) 2008-11-10
KR20020033186A (ko) 2002-05-04
KR100748823B1 (ko) 2007-08-13
CZ301585B6 (cs) 2010-04-21
IS6308A (is) 2002-03-19
EP1218009B1 (en) 2005-02-02
IS2139B (is) 2006-08-15
CN1331472C (zh) 2007-08-15
CN1899288A (zh) 2007-01-24
DE60017923D1 (de) 2005-03-10
CA2383131A1 (en) 2001-03-29
SI1218009T1 (en) 2005-06-30
NZ517549A (en) 2003-10-31
CN1188130C (zh) 2005-02-09
US6599897B1 (en) 2003-07-29
DK1218009T3 (da) 2005-05-09
AU7302300A (en) 2001-04-24
CN1626094A (zh) 2005-06-15
BG106509A (en) 2002-12-29
NO20021394D0 (no) 2002-03-20
IL148440A0 (en) 2002-09-12
HUP0203531A2 (hu) 2003-02-28
CN1374867A (zh) 2002-10-16
BR0014107A (pt) 2002-08-20
SK3722002A3 (en) 2002-07-02
BG65469B1 (bg) 2008-09-30
NO20021394L (no) 2002-03-20
JP2003509461A (ja) 2003-03-11
TR200200716T2 (tr) 2002-06-21
HK1047706B (zh) 2005-06-10
US7022692B2 (en) 2006-04-04
HK1047706A1 (en) 2003-03-07
PT1218009E (pt) 2005-05-31
TWI226832B (en) 2005-01-21
RU2256453C2 (ru) 2005-07-20
CZ2002974A3 (cs) 2002-06-12
NO320908B1 (no) 2006-02-13
EE200200150A (et) 2003-04-15
ES2235941T3 (es) 2005-07-16
CO5180585A1 (es) 2002-07-30
GB0021406D0 (en) 2000-10-18
GB9922271D0 (en) 1999-11-17
WO2001021179A1 (en) 2001-03-29
ATE288272T1 (de) 2005-02-15
EP1218009A1 (en) 2002-07-03
IL148440A (en) 2007-07-04
MXPA02002627A (es) 2002-07-30
MY130208A (en) 2007-06-29
AR032596A1 (es) 2003-11-19
PL198824B1 (pl) 2008-07-31
DE60017923T2 (de) 2006-01-12
PL357369A1 (en) 2004-07-26
AU776292B2 (en) 2004-09-02
US20060159768A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
HUP0203531A3 (en) Quetiapine granules and process for their preparation and their use
SG85153A1 (en) Polishing composition and polishing process
HK1043087A1 (en) Soluble material and process for three-dimensionalmodeling
IL147819A0 (en) Refastenable absorbent article
EP1223932A4 (en) COMPOUNDS AND METHODS
EP1146790A4 (en) COMPOUNDS AND METHODS
GB9917851D0 (en) Process
IL147818A0 (en) Refastenable absorbent article
IL147817A0 (en) Refastenable absorbent article
IL147814A0 (en) Refastenable absorbent article
GB9905512D0 (en) Process
IL147815A0 (en) Refastenable absorbent article
GB9908814D0 (en) Process
GB9914209D0 (en) Process
GB9904162D0 (en) Process
IL147816A0 (en) Refastenable absorbent article
HUP0103569A3 (en) New medicament and process for its preparation
GB9905418D0 (en) Process
HK1050026A1 (zh) 編碼β-微管蛋白的DNA及其應用
HUP0201800A2 (en) Novel calpains and their use
GB9929581D0 (en) Comjpositions and their use
GB9917330D0 (en) Process
GB9903087D0 (en) Process
GB9908564D0 (en) Novel compounds and process
SI1175428T1 (en) 3-deoxy-desmycosin derivatives and process for their preparation

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees